29:
587:
Shanks, Hayley R. C.; Börjesson‐Hanson, Anne; Windisch, Manfred; Massa, Stephen M.; Longo, Frank M.; Schmitz, Taylor W. (December 2022). "Age‐dependent effects of the p75 neurotrophin receptor modulator LM11A‐31 on
Alzheimer's disease biomarkers in a 26‐week safety and exploratory endpoint trial".
411:
Nasoohi, Sanaz; Tayefeh
Ghahremani, Pargol; Alehossein, Parsa; Elyasizadeh, Siyamak; BaniArdalan, Soha; Ismael, Saifudeen; Vatanpour, Hossein; Ahmadiani, Abolhassan; Ishrat, Tauheed (2023). "The p75 neurotrophin receptor inhibitor, LM11A-31, ameliorates acute stroke injury and modulates astrocytic
504:
Nguyen, Thuy-Vi V.; Crumpacker, Rachel H.; Calderon, Kylie E.; Garcia, Frankie G.; Zbesko, Jacob C.; Frye, Jennifer B.; Gonzalez, Selena; Becktel, Danielle A.; Yang, Tao; Tavera-Garcia, Marco A.; Morrison, Helena W.; Schnellmann, Rick G.; Longo, Frank M.; Doyle, Kristian P. (2021-12-10).
362:
Simmons, Danielle A.; Mills, Brian D.; Butler III, Robert R.; Kuan, Jason; McHugh, Tyne L.M.; Akers, Carolyn; Zhou, James; Syriani, Wassim; Grouban, Maged; Zeineh, Michael; Longo, Frank M. (2021).
447:
Simmons, Danielle A; James, Michelle L; Belichenko, Nadia P; Semaan, Sarah; Condon, Christina; Kuan, Jason; Shuhendler, Adam J; Miao, Zheng; Chin, Frederick T; Longo, Frank M (2018-08-15).
507:"Post-Stroke Administration of the p75 Neurotrophin Receptor Modulator, LM11A-31, Attenuates Chronic Changes in Brain Metabolism, Increases Neurotransmitter Levels, and Improves Recovery"
307:"Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinal vascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway"
449:"TSPO–PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31"
621:
256:"A Small Molecule p75NTR Ligand, LM11A-31, Reverses Cholinergic Neurite Dystrophy in Alzheimer's Disease Mouse Models with Mid- to Late-Stage Disease Progression"
364:"Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington's Disease: Preclinical Evidence with the p75NTR Ligand LM11A-31"
556:"Oral Administration of the p75 Neurotrophin Receptor Modulator, LM11A-31, Improves Erectile Function in a Mouse Model of Cavernous Nerve Injury"
254:
Simmons, Danielle A.; Knowles, Juliet K.; Belichenko, Nadia P.; Banerjee, Gargi; Finkle, Carly; Massa, Stephen M.; Longo, Frank M. (2014-08-25).
554:
Yin, Guo Nan; Ock, Jiyeon; Limanjaya, Anita; Minh, Nguyen Naht; Hong, Soon-Sun; Yang, Tao; Longo, Frank M.; Ryu, Ji-Kan; Suh, Jun-Kyu (2021).
305:
Elshaer, Sally L.; Alwhaibi, Abdulrahman; Mohamed, Riyaz; Lemtalsi, Tahira; Coucha, Maha; Longo, Frank M.; El-Remessy, Azza B. (2019).
78:
54:
154:
234:
230:
631:
626:
107:
526:
486:
468:
429:
383:
344:
326:
277:
597:
567:
534:
518:
476:
460:
421:
391:
375:
334:
318:
285:
267:
179:
116:
163:
517:(2). American Society for Pharmacology & Experimental Therapeutics (ASPET): 126–141.
539:
506:
481:
448:
396:
363:
339:
306:
290:
255:
615:
143:
425:
272:
572:
555:
379:
322:
212:
530:
472:
433:
387:
330:
281:
522:
490:
348:
464:
20:
601:
129:
28:
511:
211:
178:
173:
153:
128:
106:
69:
53:
48:
40:
35:
142:
115:
8:
19:
622:Experimental drugs for Alzheimer's disease
27:
571:
538:
480:
395:
338:
289:
271:
162:
246:
83:
229:is an experimental drug developed for
18:
7:
133:
98:-(2-morpholin-4-ylethyl)pentanamide
14:
196:
190:
426:10.1016/j.expneurol.2022.114161
560:The Journal of Sexual Medicine
202:
184:
1:
374:(2). Elsevier BV: 1039–1063.
273:10.1371/journal.pone.0102136
648:
590:Alzheimer's & Dementia
573:10.1016/j.jsxm.2020.10.015
380:10.1007/s13311-021-01023-8
174:Chemical and physical data
323:10.1007/s00125-019-4885-2
74:
26:
453:Human Molecular Genetics
523:10.1124/jpet.121.000711
420:. Elsevier BV: 114161.
414:Experimental Neurology
235:Huntington's disease
231:Alzheimer's disease
94:)-2-Amino-3-methyl-
23:
602:10.1002/alz.069079
465:10.1093/hmg/ddy202
121:1243259-19-9 (HCl)
459:(16): 2893–2912.
368:Neurotherapeutics
224:
223:
16:Experimental drug
639:
606:
605:
584:
578:
577:
575:
551:
545:
544:
542:
501:
495:
494:
484:
444:
438:
437:
408:
402:
401:
399:
359:
353:
352:
342:
317:(8): 1488–1500.
302:
296:
295:
293:
275:
251:
219:
204:
198:
192:
186:
166:
146:
136:
135:
119:
31:
24:
22:
647:
646:
642:
641:
640:
638:
637:
636:
612:
611:
610:
609:
586:
585:
581:
553:
552:
548:
503:
502:
498:
446:
445:
441:
410:
409:
405:
361:
360:
356:
304:
303:
299:
253:
252:
248:
243:
217:
207:
201:
195:
189:
169:
149:
132:
124:
120:
102:
99:
82:
81:
65:
62:Investigational
17:
12:
11:
5:
645:
643:
635:
634:
629:
624:
614:
613:
608:
607:
579:
546:
496:
439:
403:
354:
297:
266:(8): e102136.
245:
244:
242:
239:
222:
221:
215:
209:
208:
205:
199:
193:
187:
182:
176:
175:
171:
170:
168:
167:
159:
157:
151:
150:
148:
147:
139:
137:
126:
125:
123:
122:
112:
110:
104:
103:
101:
100:
85:
77:
76:
75:
72:
71:
67:
66:
64:
63:
59:
57:
51:
50:
46:
45:
42:
38:
37:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
644:
633:
630:
628:
625:
623:
620:
619:
617:
603:
599:
595:
591:
583:
580:
574:
569:
565:
561:
557:
550:
547:
541:
536:
532:
528:
524:
520:
516:
512:
508:
500:
497:
492:
488:
483:
478:
474:
470:
466:
462:
458:
454:
450:
443:
440:
435:
431:
427:
423:
419:
415:
407:
404:
398:
393:
389:
385:
381:
377:
373:
369:
365:
358:
355:
350:
346:
341:
336:
332:
328:
324:
320:
316:
312:
308:
301:
298:
292:
287:
283:
279:
274:
269:
265:
261:
257:
250:
247:
240:
238:
236:
232:
228:
216:
214:
210:
183:
181:
177:
172:
165:
161:
160:
158:
156:
152:
145:
141:
140:
138:
131:
127:
118:
114:
113:
111:
109:
105:
97:
93:
89:
84:
80:
73:
68:
61:
60:
58:
56:
52:
47:
43:
39:
36:Clinical data
34:
30:
25:
632:Carboxamides
593:
589:
582:
566:(1): 17–28.
563:
559:
549:
514:
510:
499:
456:
452:
442:
417:
413:
406:
371:
367:
357:
314:
311:Diabetologia
310:
300:
263:
259:
249:
226:
225:
95:
91:
87:
55:Legal status
49:Legal status
627:Morpholines
220: g·mol
117:102562-74-3
70:Identifiers
41:Other names
616:Categories
241:References
213:Molar mass
164:Y9GUF3B7Q7
108:CAS Number
79:IUPAC name
531:0022-3565
473:0964-6906
434:0014-4886
412:proNGF".
388:1878-7479
331:0012-186X
282:1932-6203
44:LM-11A-31
540:11048261
491:29860333
349:31073629
260:PLoS ONE
227:LM11A-31
144:18604758
21:LM11A-31
596:(S10).
482:6077813
397:8423954
340:8808141
291:4143160
218:243.351
180:Formula
130:PubChem
537:
529:
489:
479:
471:
432:
394:
386:
347:
337:
329:
288:
280:
527:ISSN
487:PMID
469:ISSN
430:ISSN
384:ISSN
345:PMID
327:ISSN
278:ISSN
233:and
155:UNII
598:doi
568:doi
535:PMC
519:doi
515:380
477:PMC
461:doi
422:doi
418:359
392:PMC
376:doi
335:PMC
319:doi
286:PMC
268:doi
134:CID
618::
594:18
592:.
564:18
562:.
558:.
533:.
525:.
513:.
509:.
485:.
475:.
467:.
457:27
455:.
451:.
428:.
416:.
390:.
382:.
372:18
370:.
366:.
343:.
333:.
325:.
315:62
313:.
309:.
284:.
276:.
262:.
258:.
237:.
194:25
188:12
90:,3
86:(2
604:.
600::
576:.
570::
543:.
521::
493:.
463::
436:.
424::
400:.
378::
351:.
321::
294:.
270::
264:9
206:2
203:O
200:3
197:N
191:H
185:C
96:N
92:S
88:S
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
